The global neurometabolic disorders market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising number of various neurometabolic disorders and increasing demand for rapid diagnostic techniques over current procedures.
Abnormalities that impact brain functions are known as neurometabolic disorders or neurogenetic illnesses. The disorders are caused by abnormal gene functioning, which can lead to a variety of chronic & rare diseases and affect people of various ages. At present, there is no specific treatment or cure for the disorders. Thus, a correct diagnosis is necessary to identify the underlying reason. The findings of the analytical and clinical study point to substantial progress in understanding biochemical abnormalities, etiology, molecular genetics, and diagnostic tests for this condition. The steady breakdown of mental and perceptual functions are the principal symptoms of neurometabolic disorders.
Furthermore, multiple organs are affected by neurometabolic disorders and the disease symptoms range from acute life-threatening disease to subacute progressive degenerative disorders. Amino acid apathies and organic acidurias are the most common neurometabolic disorders, followed by congenital lactic acidosis, lipofuscinoses, peroxisomal disorders, and neuronal ceroid urea cycle disorders with mucopolysaccharidoses, degradation disorders, sphingolipidoses, glycoprotein, and fatty acid oxidation disorders being the least common.
Due to the COVID–19 pandemics, the ophthalmic drugs market is expected to get hampered due to emergency lockdown imposed by several governments of every major economy. The pandemic had led to shut the manufacturing units worldwide. As hospitals are packed with COVID-19 patients, the number of people visiting to eye clinics or hospitals are reduced significantly and only emergency treatments are being performed.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing healthcare expenditures and growing awareness level related to neurometabolic disorders are expected to boost the market growth.
- Rising number of clinical trials and increasing demand for technologically advanced therapeutics are anticipated to propel the market expansion during the forecast period.
- Growing funds & grants by government in R&D activities is expected to upsurge the market growth.
- High cost involved in neuro-research & development affects the market share in low & middle income level countries. This is expected to hamper the market growth in the coming years.
- Early stage drugs approval by regulatory bodies and geographical expansion of key pharma companies in emerging countries are offering immense opportunity for market growth in the long run.
Scope of the Report
The report on the global neurometabolic disorders market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Neurometabolic Disorder Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types (Fabry disease, Niemann-pick Type C Disease, Gaucher's Disease, Pompe Disease, and Mucopolysaccharidosis VI) and Routes of Administration (Parenteral and Oral)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
UAB Proforma; Amicus Therapeutics; ISU Abxis; Protalix Bio Therapeutics; JCR Pharmaceuticals; Biosidus SA; Neuraltus Pharmaceuticals; Greenovation Biotech; Greencross; Dong-A Socio Group; ExSAR Corp.; Lixte Biotechnology Holdings, Inc.; Pharming Group N.V.; Protalix BioTherapeutics; Sanofi Genzyme; Amicus Therapeutics; and Biomarin Pharmaceutical Inc.
|
Market Segment Insights
Gaucher's disease segment is expected to grow at a robust pace
Based on types, the global neurometabolic disorders market is segmented into fabry disease, niemann-pick type c disease, gaucher's disease, pompe disease, and mucopolysaccharidosis VI. The gaucher's disease segment is expected to grow at a robust pace during the forecast period. The growth of the segment attributed to the increasing number of cases of this disorder and further rising demand for therapeutics.
Moreover, low blood platelets, anemia, fatigue, bruising, and enlargement of the liver & spleen distinguish the illness. Cerezyme, a Genzyme (Sanofi SA) company, and velaglucerase alfa for injection (VPRIV), a Shire Plc subsidiary, are the two main medications used to treat Gaucher's disease.
Oral segment is projected to expand at a considerable CAGR
On the basis of routes of administration, the market is bifurcated into parenteral and oral. The oral segment is projected to expand at a considerable CAGR during the forecast period owing to the increasing adoption of oral therapies for the treatment of numerous disorders. Furthermore, oral delivery technology can improve a drug's efficacy even when the same amount is consumed, and this advancement reduce production costs, lowering the cost of therapy for the patient. As a result, both pharma companies and patients benefit from these innovations. Thus, it is expected to fuel the segment growth in the coming years.
North America is anticipated to constitute a key market share
In terms of regions, the global neurometabolic disorders market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the various research and development in the area of bioinformatics and transcriptomic to integrate the gene level study of the disorder. Genomic-based biopharmaceutical research, medication design, and increased awareness for diagnosis and treatment in the adolescent population are some of the major factors propelling the market expansion in region.
Moreover, the presence of numerous economic leverages such as exemption from prescription drug fees for orphan drugs, tax credits for approved clinical studies, and seven years of market exclusivity for diagnostics by the United States Food and Drug Administration (FDA) are projected to fuel the market growth.
Segments
The global neurometabolic disorders market has been segmented on the basis of
Types
- Fabry disease
- Niemann-pick Type C Disease
- Gaucher's Disease
- Pompe Disease
- Mucopolysaccharidosis VI
Routs of Administration
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- UAB Proforma
- Amicus Therapeutics
- ISU Abxis
- Protalix Bio Therapeutics
- JCR Pharmaceuticals
- Biosidus SA
- Neuraltus Pharmaceuticals
- Greenovation Biotech
- Greencross
- Dong-A Socio Group
- ExSAR Corp.
- Lixte Biotechnology Holdings, Inc.
- Pharming Group N.V.
- Protalix BioTherapeutics
- Sanofi Genzyme
- Amicus Therapeutics
- Biomarin Pharmaceutical Inc.
Competitive Landscape
Some of the key players competing in the global neurometabolic disorders market are UAB Proforma; Amicus Therapeutics; ISU Abxis; Protalix Bio Therapeutics; JCR Pharmaceuticals; Biosidus SA; Neuraltus Pharmaceuticals; Greenovation Biotech; Greencross; Dong-A Socio Group; ExSAR Corp.; Lixte Biotechnology Holdings, Inc.; Pharming Group N.V.; Protalix BioTherapeutics; Sanofi Genzyme; Amicus Therapeutics; and Biomarin Pharmaceutical Inc.
To expand their market reach, major market players are engaged in innovation and development of new products. Furthermore, these key players are stepping into merger & acquisitions, licensing partnerships, and co-development to stay ahead in the market competition.
Request For Customization
Enquiry Before Buying
Speak With Analyst
